Request to Join
has invited you to join this group
Dr. Murphy has worked as a researcher in the areas of aging and neurodegenerative disease for more than 20 years, starting with an M.A. degree, in Psychology, and a Ph.D., in Neuroscience (both at the University of Toronto). Dr. Murphy began to focus on Alzheimer’s disease (AD) while a post-doctoral fellow at the Mayo Clinic in Jacksonville, FL, and has authored or co-authored over 100 peer reviewed manuscripts, with especially notable publications in Annals of Neurology, Journal of Neuroscience, American Journal of Pathology, Science, and Nature Medicine. His lab studies the production of the amyloid-β peptide (Aβ), the regulation of these processes, and how the peptide ultimately forms pathologic structures in the brain. Over his career, he has engaged in research involving basic cell and molecular biology, preclinical translational studies, and human clinical trials. Dr. Murphy has been involved with the generation and characterization of multiple mouse models that are widely used in the AD field, including the first models of combined amyloid and tau pathology, as well as newer models incorporating aspects of vascular and metabolic disease. He has been faculty at the University of Kentucky in the Department of Molecular and Cellular Biochemistry, and the Sanders-Brown Center on Aging, since 2005.
Pete is an experimental neuropathologist interested in neurodegenerative diseases. Following a PhD in Dr. Clif Saper’s lab focusing on animal models of neurodegeneration, Pete was trained in neurodegenerative disease neuropathology by Dr. John Trojanowski at University of Pennsylvania. Pete’s work at the University of Kentucky has provided insights into the associative impact of pathology in the aged brain, and how genetics may play a role in neurodegenerative diseases. Pete contributed to key papers on primary age-related tauopathy (PART), cerebral age-related TDP-43 with sclerosis (CARTS), and brain arteriolosclerosis. Pete also helped produce scholarship defining the neuropathologic features underlying diabetes (not Alzheimer’s disease), and the disease substrates (also often not Alzheimer’s disease!) that underlie subjective memory complaints and MCI. Teasing apart the features that delineate each AD mimicking disease provides an exciting opportunity to obtain new disease-modifying or disease-prevention strategies. In addition to duties as a neuropathologist, Pete is an experimental researcher focusing on the molecular neurochemistry of the human brain — in health and in neurodegenerative disease — particularly in the context of RNA biology. Pete is one of two PIs (along with Dr. Gregory Jicha; R01 AG042419 ) working on a IIRG/preliminary clinical trial to assess the potential for using a PPAR-alpha agonist drug as an AD therapeutic, possibly via a miRNA-related mechanism. Pete’s career is motivated partly by his own grandmother, Sylvia “Tib” Becker, who died with Alzheimer's disease.
Professor of psychiatry, neurology, and gerontology at the Keck School of Medicine of the University of Southern California
The laboratory of Clifford R. Jack Jr., M.D., is engaged in brain imaging research in cognitive aging, Alzheimer's disease and related disorders. Dr. Jack's research team employs MRI and positron emission tomography (PET) to study the biology of brain aging and causes of cognitive impairment and develops image-processing algorithms for quantitatively measuring the information obtained from brain imaging. They employ a variety of MRI-based brain imaging modalities, including structural MRI, spectroscopy, functional connectivity and brain water diffusion. They also employ F-fluorodeoxyglucose positron emission tomography (FDG-PET) and amyloid PET. The lab's clinical imaging research is tightly integrated into the Mayo Clinic Alzheimer's Disease Patient Registry (Mayo Clinic Study of Aging) and Mayo's Alzheimer's Disease Research Center, which conduct National Institutes of Health-funded longitudinal clinical and epidemiological research projects investigating normal aging, Alzheimer's disease and other dementias. Dr. Jack also collaborates with a number of investigators outside Mayo, and his laboratory is the imaging center for several large national multisite studies.
Dr. Guy McKhann is Professor of Neurology at the Johns Hopkins School of Medicine. He has a joint appointment in the Department of Neuroscience at the School of Medicine. Dr. McKhann was the founding chairman of the Department of Neurology at the Johns Hopkins School of Medicine and was also the founding director of The Zanvyl Krieger Mind/Brain Institute at Johns Hopkins University. Dr. McKhann has authored over 200 publications. His clinical research has included studies of the Guillain-Barre Syndrome, which included research programs in the United States as well as in China. His most recent research has focused on the role of vascular factors in cognitive decline. He was co-editor for many years of a successful neurology textbook, Diseases of the Nervous System: Clinical Neurobiology. He and his colleague (and wife) Dr. Marilyn Albert published a book about aging and the brain for the general public entitled Keep Your Brain Young. Dr. McKhann has been involved with a number of scientific organizations, including as president of the American Neurological Association. He was formerly the Chairman of the Scientific Advisory Group for United Cerebral Palsy. He has also been an advisor to the Vatican on issues relating to the end of life care, particularly for patients with ‘brain death’. He is currently the Scientific Advisor to the Charles A. Dana Foundation. Dr. McKhann attended Harvard University and received his MD degree from the Yale University School of Medicine.
Jeffrey Savas received a Bachelor of Science in Biochemistry and Molecular Biology at the University of California, Santa Cruz. He received his PhD from New York University School and performed his postdoctoral training at The Scripps Research Institute in La Jolla. Savas Lab opened at Northwestern University in February of 2015. Research in the Savas lab is aimed at accelerating our understanding of the proteins and proteomes responsible for neurodevelopmental and neurodegenerative diseases. We use biochemistry with discovery-based mass spectrometry to identify the protein perturbations which drive synaptopathies and proteinopathies.
Dr. Salloway received his medical degree from Stanford University Medical School. He completed residencies in neurology and psychiatry at Yale University Medical School. He has authored over 200 journal articles, book chapters, and abstracts and edited three books on prevention and early detection of Alzheimer’s disease. He is a global leader in research and treatment of Alzheimer's disease.
Dr. Carrillo is Chief Science Officer, Medical and Scientific Relations Division, at the Alzheimer’s Association. At the Association, Dr. Carrillo has a wide range of responsibilities, including oversight of the Association's grantmaking process and communication of scientific findings within and outside of the organization. Dr. Carrillo oversees the international science division for the Alzheimer’s Association, and also manages several Association initiatives. One of these is the Alzheimer's Association International Conference, the largest international discussion on Alzheimer’s and related dementias in the world. Another is the Alzheimer’s Association Research Roundtable, which provides a forum for pharmaceutical companies to discuss trends in Alzheimer research and therapeutic targets. Dr. Carrillo manages the World-Wide Alzheimer’s Disease Neuroimaging Initiative (WW-ADNI), which is a multi-country research effort aimed at finding biomarkers for early detection of Alzheimer’s. She leads the Alzheimer’s Association’s GAAIN project, which is a global federated network to support all publicly accessible data in dementia. Dr. Carrillo is on the Advisory Committee for the World Health Organization Dementia Setting Priorities & Portfolio Analysis. She is a member of the National Advisory Council on Aging, which advises the Secretary of the U.S. Department of Health and Human Services, and the Directors of the U.S National Institutes of Health and National Institute on Aging. In 2016, Dr. Carrillo joined the Governing Board of the Global Brain Health Institute, which is reducing the and impact of dementia around the world by training and supporting a new generation of leaders to translate research evidence into effective policy and practice. Also in 2016, Dr. Carrillo became a member of the American Heart Association’s Research Committee. Dr. Carrillo has published extensively on early diagnosis and biomarker standardization efforts in Alzheimer’s disease, in addition to global challenges to Alzheimer’s and dementia research progress. She is co-author of the NIA-AA revised criteria for diagnosis of Alzheimer’s, and the Appropriate Use Criteria for Amyloid Imaging. She was an Advisory Committee member for The Shriver Report, and co-editor of Modernizing the Diagnosis of Alzheimer’s Disease. In 2014, Dr. Carrillo was the Alzheimer’s Expert Scientific Consultant for the movie Still Alice. Dr. Carrillo received her Ph.D. from Northwestern University’s Institute for Neuroscience in 1996. Since graduating from Northwestern, she completed a postdoctoral fellowship in the Division of Neurological Sciences at Rush University Medical Center in Chicago, where she later took a position as an assistant professor. Before joining the Association Dr. Carrillo was also an Advisor at the University of Chicago.
Tamar Gefen, PhD received her PhD from Northwestern University and completed fellowship at MGH/Harvard Medical School. Her research interests involve examining the cognitive and pathologic correlates of age-related neurodegenerative diseases.
Dr. Michael Gold currently serves as Vice-president for CNS Development at AbbVie. Prior to joining AbbVie, Dr. Gold spent several years in large pharmaceutical companies (BMS, J&J and GSK) in roles of increasing responsibility as well as in senior leadership roles in several biotech companies (CMO of Allon Therapeutics and Accera Inc.), in a specialty pharmaceutical company (UCB) and a short stint in a CRO (PPD). Dr. Gold has worked across all stages of CNS drug development, on small molecules, biologicals, drug-device combinations and diagnostics. Dr. Gold and his teams have worked on compounds for AD, PD, Stroke, RLS, migraine, epilepsy, MS, chronic somatic and neuropathic pain resulting in a number of successful approvals in the US, EU and Japan. Dr. Gold earned his BS (Chemistry, cum laude), MS (Mathematics and Computer Science) and MD degrees at the University of Miami, completed his Neurology training at the Albert Einstein College of Medicine in New York and then completed a fellowship in Behavioral Neurology at the University of Florida College of Medicine. After completing his training, Dr. Gold was appointed as an Assistant Professor in the Department of Neurology at the University of South Florida (Tampa) where he provided care for patients, trained medical students, residents and fellows. During his tenure at USF, Dr. Gold was appointed as the Medical Director for USF’s Memory Disorder Clinic, where patients from a large catchment area with a broad range of cognitive impairments were evaluated, treated and offered participation in clinical trials. Over the last 20 years, Dr. Gold has been involved in a large number of clinical trials for neurodegenerative disorders from the investigator, sponsor and CRO perspectives and has continuously pushed for the adoption of innovative designs in clinical trials. Dr. Gold has served on a number of Scientific Advisory Boards for biotech companies, serves as a grant reviewer for several philanthropic organizations and serves as an editor and reviewer for several peer-reviewed medical journals and has been invited to present at several international scientific conferences. Dr. Gold is an author of approximately 50 peer-reviewed publications.